Merck Recalls Cholesterol Medicine Due to Packaging Defect - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck Recalls Cholesterol Medicine Due to Packaging Defect


Merck, known as MSD outside the United States and Canada, is voluntarily recalling all lots of Liptruzet (ezetimibe and atorvastatin) 10/10 mg, 10/20 mg, 10/40 mg, and 10/80 mg tablets in the United States, including Puerto Rico, due to packaging defects, the company announced in a press release. The recall affects wholesalers but not patients or pharmacies. Stock-outs are expected, but Merck is committed to resupplying Liptruzet as soon as possible.

Merck is recalling from wholesalers all lots of Liptruzet that have been distributed since the product was introduced in May 2013. Some of the outer laminate-foil pouches may allow in air and moisture, which could potentially decrease the effectiveness or change the characteristics of the product. The likelihood of the packaging defects decreasing the effectiveness of Liptruzet on a patient’s lipid profile or negatively impacting the safety of the product is remote. The decision to recall Liptruzet was not based on any reported adverse experiences or product quality complaints.

The recall will deplete all available supply in the US. The two active ingredients remain available: Zetia (ezetimibe) is available from Merck, and atorvastatin is available as a generic from multiple manufacturers. The recall does not affect any other products manufactured by Merck.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here